![]() ![]() He is presently the principal investigator at the BWH AIDS Clinical Trials Unit, and is a member of the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) Research Group. Sax’s ongoing areas of research include clinical trials of antiretroviral therapies, cost-effectiveness of management strategies for HIV, and toxicity of antiretroviral therapy. In addition to his clinical practice and teaching, Dr. Sax is Clinical Director of the Division of Infectious Diseases at Brigham and Womens Hospital and Professor of Medicine at Harvard Medical School. Sax is also on the core faculty of the International AIDS Society – USA and the New England AIDS Education and Training Center. ![]() He is Editor-in-Chief of Open Forum Infectious Diseases, is Section Editor of HIV/AIDS in UpToDate, on the Editorial Board of NEJM Journal Watch Infectious Diseases (where he writes the HIV and ID Observations blog), and on the editorial advisory board of Medscape HIV/AIDS. Sax received his MD from Harvard Medical School, then did his residency in Internal Medicine at BWH, then fellowship in Infectious Diseases at Massachusetts General Hospital. Sax is Clinical Director of the Division of Infectious Diseases and the HIV Program at Brigham and Women’s Hospital (BWH), and Professor of Medicine at Harvard Medical School. The study, “ Sustained HIV-1 Remission Following Homozygous CCR5 Delta32 Allogenic HSCT,” was presented on Tuesday, March 5, 2019, at the Annual Conference on Retroviruses and Opportunistic Infections ( CROI) 2019 in Seattle, Washington.Emma Levine presents a clinical unknown to Dr. However, this is by no means a scalable intervention for millions of people who have HIV, but it does show us, though, is that that first case was not just a one-off, that there are potentially other ways of achieving the same thing. So there were a lot of similarities between this case and the person who has been cured previously. Now, this person has been off treatment for well over a year now and he hasn't relapsed and, furthermore, he received the same treatment of the first cure, which is that he required a stem cell or bone marrow transplant-they mean pretty much the same thing-for treatment of underlying hematologic malignancy and received cells that were CCR5 negative and these CCR5 negative cells cannot be infected by viruses that use the CCR5 receptor to enter the cell. We have been fooled with certain individuals previously who had been off their treatment for many months and yet ultimately relapsed. Paul Sax, MD: "Well I do think it's appropriate that in a person who has this long-term remission from HIV that we not prematurely call it a cure. ![]() What is your reaction to the news that a second person has achieved long-term HIV remission? Is it too early to call this a cure? Interview transcript: (modified slightly for readability)Ĭontagion®: News of the London patient broke Monday night. Segment Description: Paul Sax, MD, clinical director in the Division of Infectious Diseases at Brigham and Women's Hospital, shares his take on news of the second person ever achieving long-term HIV remission. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |